Ling W, Nadipelli V, Solem C, Ronquest NA, Yeh YC, Heidbreder C, Learned S, Mehra V. Impact of RBP-6000 (depot buprenorphine) on patient-reported life changes: a long-term study. Presented at the Australasian Professional Society on Alcohol and other Drugs 49th Annual Conference; November 7, 2018. Auckland, Australia. Previously presented at the American Society of Addiction Medicine 49th Annual Conference.
Ronquest NA, Willson TM, Montejano LB, Nadipelli VR, Wollschlaeger BA. Relationship between buprenorphine adherence and relapse, health care utilization and costs in privately and publicly insured patients with opioid use disorder. Subst Abuse Rehabil. 2018 Sep 21;9:59-78. doi: 10.2147/SAR.S150253
Wollschlaeger BA, Ronquest NA, Montejano LB, Wilson TM, Nadipelli VR. Narcotic pain medication and other concomitant medication use before and after buprenorphine maintenance treatment initiation in patients with opioid dependence. Poster presented at the 2016 PAINWeek Conference; September 2016. Las Vegas, NV. [abstract] Postgrad Med. 2018 Aug; 128(Sup2):63-4. doi: 10.1080/00325481.2016.1224633
Ling W, Nadipelli VR, Solem CT, Ronquest NA, Yeh Y, Heidbrede C, Learned SM. Impact of RBP-6000 (depot buprenorphine) on patient-reported outcomes: a long-term study. Poster presented at the American Society of Addiction Medicine 49th Annual Conference; April 13, 2018. San Diego, CA.